Unlike a measure based only on intrinsic spin-spin relaxation, T2* is also sensitive to local magnetic-field variations. Gradient-echo signal therefore falls because microscopic susceptibility differences add to transverse dephasing. This makes the value responsive to sources such as deoxygenated blood, hemorrhage, iron, and calcification, but also means it represents combined tissue and susceptibility effects rather than a single property.
These substances act as susceptibility sources that disturb the local magnetic field. The resulting field variations accelerate loss of transverse magnetization during gradient-echo imaging, altering the measured T2* value. Consequently, regions containing hemorrhage, iron, calcification, or deoxygenated blood may contribute to signal behavior that reveals tissue features not readily apparent on conventional anatomical MRI.
Spatial differences in T2* can reflect variation in vascularity, oxygenation, blood products, iron, or calcification within a tumor. Such variation may indicate that the lesion is not uniform, even when its anatomical appearance seems relatively consistent. Mapping these differences therefore adds a susceptibility-sensitive view of tumor composition and supports more detailed characterization.
Gradient-echo imaging is sensitive to signal loss produced by both intrinsic transverse relaxation and magnetic-field variations. That sensitivity allows T2* mapping to capture susceptibility effects associated with tumor blood, oxygenation, hemorrhage, iron, or calcification. The resulting measurements complement conventional anatomical images by emphasizing relaxation behavior and local field differences rather than structure alone.
T2* mapping can support assessment of tumor vascularity, oxygenation, blood products, and tissue heterogeneity. These characteristics provide complementary information to conventional anatomical MRI, which may not display all of the underlying tissue differences. In practice and research, the measurement contributes to a broader picture of tumor composition when interpreted alongside other imaging findings.
Serial T2* measurements may provide information about treatment-related effects by showing how susceptibility-sensitive tissue behavior changes over time. Such changes can be considered alongside anatomical imaging and other MRI biomarkers rather than interpreted in isolation. This longitudinal use supports research into therapy response and may help identify imaging changes associated with evolving tumor tissue.
T2* is influenced by several overlapping factors, including spin-spin relaxation and susceptibility sources. A single value may therefore reflect multiple tissue processes rather than one definitive biological feature. Combining it with other MRI biomarkers can improve tumor characterization by integrating complementary information and can strengthen research evaluations of vascularity, oxygenation, heterogeneity, and therapy-related change.